Ventricular nanosecond pulsed electric field delivery using active fixation leads: a proof-of-concept preclinical study.
Cardiac ablation
Electroporation
Pulsed electric field
Ventricular tachycardia
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
30 Jun 2022
30 Jun 2022
Historique:
received:
15
05
2022
accepted:
02
06
2022
entrez:
30
6
2022
pubmed:
1
7
2022
medline:
1
7
2022
Statut:
aheadofprint
Résumé
Mid-myocardial ventricular arrhythmias are challenging to treat. Cardiac electroporation via pulsed electric fields (PEFs) offers significant promise. We therefore tested PEF delivery using screw-in pacemaker leads as proof-of-concept. In 5 canine models, we applied nanosecond PEF (pulse width 300 ns) across the right ventricular (RV) septum using a single lead bipolar configuration (n = 2) and between two leads (n = 3). We recorded electrograms (EGMs) prior to, immediately post, and 5 min after PEF. Cardiac magnetic resonance imaging (cMRI) and histopathology were performed at 2 weeks and 1 month. Nanosecond PEF induced minimal extracardiac stimulation and frequent ventricular ectopy that terminated post-treatment; no canines died with PEF delivery. With 1 lead, energy delivery ranged from 0.64 to 7.28 J. Transient ST elevations were seen post-PEF. No myocardial delayed enhancement (MDE) was seen on cMRI. No lesions were noted on the RV septum at autopsy. With 2 leads, energy delivery ranged from 56.3 to 144.9 J. Persistent ST elevations and marked EGM amplitude decreases developed post-PEF. MDE was seen along the septum 2 weeks and 1 month post-PEF. There were discrete fibrotic lesions along the septum; pathology revealed dense connective tissue with < 5% residual cardiomyocytes. Ventricular electroporation is feasible and safe with an active fixation device. Reversible changes were seen with lower energy PEF delivery, whereas durable lesions were created at higher energies. Central illustration: pulsed electric field delivery into ventricular myocardium with active fixation leads.
Sections du résumé
BACKGROUND
BACKGROUND
Mid-myocardial ventricular arrhythmias are challenging to treat. Cardiac electroporation via pulsed electric fields (PEFs) offers significant promise. We therefore tested PEF delivery using screw-in pacemaker leads as proof-of-concept.
METHODS
METHODS
In 5 canine models, we applied nanosecond PEF (pulse width 300 ns) across the right ventricular (RV) septum using a single lead bipolar configuration (n = 2) and between two leads (n = 3). We recorded electrograms (EGMs) prior to, immediately post, and 5 min after PEF. Cardiac magnetic resonance imaging (cMRI) and histopathology were performed at 2 weeks and 1 month.
RESULTS
RESULTS
Nanosecond PEF induced minimal extracardiac stimulation and frequent ventricular ectopy that terminated post-treatment; no canines died with PEF delivery. With 1 lead, energy delivery ranged from 0.64 to 7.28 J. Transient ST elevations were seen post-PEF. No myocardial delayed enhancement (MDE) was seen on cMRI. No lesions were noted on the RV septum at autopsy. With 2 leads, energy delivery ranged from 56.3 to 144.9 J. Persistent ST elevations and marked EGM amplitude decreases developed post-PEF. MDE was seen along the septum 2 weeks and 1 month post-PEF. There were discrete fibrotic lesions along the septum; pathology revealed dense connective tissue with < 5% residual cardiomyocytes.
CONCLUSIONS
CONCLUSIONS
Ventricular electroporation is feasible and safe with an active fixation device. Reversible changes were seen with lower energy PEF delivery, whereas durable lesions were created at higher energies. Central illustration: pulsed electric field delivery into ventricular myocardium with active fixation leads.
Identifiants
pubmed: 35771400
doi: 10.1007/s10840-022-01268-z
pii: 10.1007/s10840-022-01268-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Dinov B, Fiedler L, Schonbauer R, et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation. 2014;129:728–36.
doi: 10.1161/CIRCULATIONAHA.113.003063
Kuck KH, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375:31–40.
doi: 10.1016/S0140-6736(09)61755-4
Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375:111–21.
doi: 10.1056/NEJMoa1513614
Neira V, Santangeli P, Futyma P, et al. Ablation strategies for intramural ventricular arrhythmias. Heart Rhythm. 2020;17:1176–84.
doi: 10.1016/j.hrthm.2020.02.010
Tung R, Raiman M, Liao H, et al. Simultaneous endocardial and epicardial delineation of 3D reentrant ventricular tachycardia. J Am Coll Cardiol. 2020;75:884–97.
doi: 10.1016/j.jacc.2019.12.044
Nguyen DT, Tzou WS, Sandhu A, et al. Prospective multicenter experience with cooled radiofrequency ablation using high impedance irrigant to target deep myocardial substrate refractory to standard ablation. JACC Clin Electrophysiol. 2018;4:1176–85.
doi: 10.1016/j.jacep.2018.06.021
Stevenson WG, Tedrow UB, Reddy V, et al. Infusion needle radiofrequency ablation for treatment of refractory ventricular arrhythmias. J Am Coll Cardiol. 2019;73:1413–25.
doi: 10.1016/j.jacc.2018.12.070
Tavares L, Lador A, Fuentes S, et al. Intramural venous ethanol infusion for refractory ventricular arrhythmias: outcomes of a multicenter experience. JACC Clin Electrophysiol. 2020;6:1420–31.
doi: 10.1016/j.jacep.2020.07.023
Maor E, Sugrue A, Witt C, et al. Pulsed electric fields for cardiac ablation and beyond: a state-of-the-art review. Heart Rhythm. 2019;16:1112–20.
doi: 10.1016/j.hrthm.2019.01.012
Wittkampf FHM, van Es R, Neven K. Electroporation and its relevance for cardiac catheter ablation. JACC Clin Electrophysiol. 2018;4:977–86.
doi: 10.1016/j.jacep.2018.06.005
van Zyl M, Ladejobi AO, Tri JA, et al. Reversible atrioventricular conduction impairment following bipolar nanosecond electroporation of the interventricular septum. JACC Clin Electrophysiol. 2021;7:255–7.
doi: 10.1016/j.jacep.2020.10.004
Sugrue A, Vaidya VR, Livia C, et al. Feasibility of selective cardiac ventricular electroporation. PLoS ONE. 2020;15: e0229214.
doi: 10.1371/journal.pone.0229214
Dickow J, Suzuki A, Henz BD, et al. Characterization of lesions created by a heated, saline irrigated needle-tip catheter in the normal and infarcted canine heart. Circ Arrhythm Electrophysiol. 2020;13: e009090.
doi: 10.1161/CIRCEP.120.009090
Buist TJ, Groen MHA, Wittkampf FHM, et al. Efficacy of multi-electrode linear irreversible electroporation. Europace. 2021;23:464–8.
doi: 10.1093/europace/euaa280
Reddy VY, Neuzil P, Koruth JS, et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol. 2019;74:315–26.
doi: 10.1016/j.jacc.2019.04.021
Sugrue A, Vaidya V, Witt C, et al. Irreversible electroporation for catheter-based cardiac ablation: a systematic review of the preclinical experience. J Interv Card Electrophysiol. 2019;55:251–65.
doi: 10.1007/s10840-019-00574-3
van Driel VJ, Neven KG, van Wessel H, et al. Pulmonary vein stenosis after catheter ablation: electroporation versus radiofrequency. Circ Arrhythm Electrophysiol. 2014;7:734–8.
doi: 10.1161/CIRCEP.113.001111
Koruth JS, Kuroki K, Iwasawa J, et al. Endocardial ventricular pulsed field ablation: a proof-of-concept preclinical evaluation. Europace. 2020;22:434–9.
doi: 10.1093/europace/euz341
Yavin HD, Higuchi K, Sroubek J, Younis A, Zilberman I, Anter E. Pulsed-field ablation in ventricular myocardium using a focal catheter: the impact of application repetition on lesion dimensions. Circ Arrhythm Electrophysiol. 2021;14: e010375.
doi: 10.1161/CIRCEP.121.010375
Epstein AE, Kay GN, Plumb VJ, Dailey SM, Anderson PG. Gross and microscopic pathological changes associated with nonthoracotomy implantable defibrillator leads. Circulation. 1998;98:1517–24.
doi: 10.1161/01.CIR.98.15.1517
Holt PM, Boyd EG, Crick JC, Sowton E. Low energies and Helifix electrodes in the successful ablation of atrioventricular conduction. Pacing Clin Electrophysiol. 1985;8:639–45.
doi: 10.1111/j.1540-8159.1985.tb05875.x
Holt P, Boyd EG. Developments in the high energy endocardial ablation technique: towards low energies. Int J Cardiol. 1986;13:1–7.
doi: 10.1016/0167-5273(86)90074-4
An HL, Saksena S, Janssen M, Osypka P. Radiofrequency ablation of ventricular myocardium using active fixation and passive contact catheter delivery systems. Am Heart J. 1989;118:69–77.
doi: 10.1016/0002-8703(89)90074-4